CEO: international outlook is needed to secure capital
Kissing a whole bunch of frogs in the hope of finding a prince might not be the way to go, says the CEO of Medicon Valley Alliance, about the roles of the Danish state and venture capital market in investing in new biotech companies. An international outlook can help bridge the gap over “the valley of death”.
af LEONORA BECK
Companies that have a difficult time attracting capital are bound to complain about a lack of capital in general. But it does not mean that the perceived lack of capital is real, says Stig Jørgensen, CEO of the Danish biotech cluster-organization Medicon Valley Alliance.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler:
Life science top of the heap for EU venture capital
For abonnenter
Less venture capital for Danish life science
For abonnenter
